USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
COMPENDIA BIOSCIENCE, INC.
Address:
110 MILLER AVE, 2ND FL
ANN ARBOR, MI 48104-
Phone:
N/A
URL:
N/A
EIN:
120415482
DUNS:
789478679
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,655,689.00 3
SBIR Phase II $3,423,270.00 2

Award List:

Development of Oncomine Professional as a Platform for Biopharmaceutical Research

Award Year / Program / Phase:
2007 / SBIR / Phase I
Award Amount:
$179,109.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): DNA microarray studies, largely sponsored by the NIH and other granting agencies, have generated a wealth of data uncovering the complex gene expression patterns of cancer. Currently however, there is no unifying organ izational or bioinformatics resource to… More

Development of Oncomine Professional as a Platform for Biopharmaceutical Research

Award Year / Program / Phase:
2008 / SBIR / Phase II
Award Amount:
$2,248,644.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): DNA microarray studies, largely sponsored by the NIH and other granting agencies, have generated a wealth of data uncovering the complex gene expression patterns of cancer. Currently however, there is no unifying organ izational or bioinformatics resource to… More

Biodata Management of Genomics Data from Cancer Cell Lines and Tumors

Award Year / Program / Phase:
2009 / SBIR / Phase I
Award Amount:
$151,358.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): It is now clear that response to targeted therapies in cancer is dictated by the molecular characteristics of an individual patient's tumor. The industry is increasingly looking to genomics-based analyses to link drug r esponse phenotypes to underlying genetic… More

Incorporating microRNA data and analyses into the leading cancer genomics portal

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$1,325,222.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Micro-RNAs (miRNAs) are small non-coding RNAs that control gene expression by regulating messenger (mRNA) translation. miRNAs can act as oncogenes or tumor suppressors, and the differential expression of miRNAs has been correlated with cancer diagnosis, staging,… More

Incorporating microRNA data and analyses into the leading cancer genomics portal

Award Year / Program / Phase:
2011 / SBIR / Phase II
Award Amount:
$1,174,626.00
Agency:
HHS
Principal Investigator:
Daniel R. Rhodes – 734-904-0365
Abstract:
DESCRIPTION (provided by applicant): Micro-RNAs (miRNAs) are small non-coding RNAs that control gene expression by regulating messenger (mRNA) translation. miRNAs can act as oncogenes or tumor suppressors, and the differential expression of miRNAs has beencorrelated with cancer diagnosis, staging,… More